Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
The purpose of this study is to assess the maintenance of efficacy of LY2216684 compared with placebo as add on therapy to SSRI among patients with Major Depressive Disorder and patients with partial response to SSRI treatment that met the remission criterion with add on LY2216684 during open-label treatment.
Who may be Eligible
Male or female 18 to 65 with a diagnosis of Major Depressive Disorder